| 13.12 -0.03 (-0.23%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.58 | 1-year : | 16.01 |
| Resists | First : | 13.34 | Second : | 13.71 |
| Pivot price | 13.04  |
|||
| Supports | First : | 12.76 | Second : | 10.61 |
| MAs | MA(5) : | 12.97  |
MA(20) : | 13.14 |
| MA(100) : | 13.49 |
MA(250) : | 13.2 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 49.4 |
D(3) : | 32 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 14.36 | Low : | 11.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HQL ] has closed below upper band by 39.8%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.21 - 13.28 | 13.28 - 13.32 |
| Low: | 12.93 - 13.02 | 13.02 - 13.08 |
| Close: | 12.99 - 13.13 | 13.13 - 13.21 |
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Fri, 05 Apr 2024
Top Picks 2020- Tekla Life Sciences Fund HQL - AOL
Thu, 21 Mar 2024
abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ ... - Kansas City Star
Mon, 26 Jun 2023
THQ CEF: Watch Out For The Merger - Seeking Alpha
Sat, 16 Oct 2021
Healthcare Is About To Soar, And These 6%+ Dividends Will Profit - Forbes
Sat, 11 Jan 2020
The 3 Most Underappreciated Income Funds On The Planet - Forbes
Fri, 12 Jul 2019
3 Dividends of Up to 15.9% – Delivered Monthly! – Contrarian Outlook - Contrarian Outlook
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 27 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 35.4 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 56 (K) |
| EPS | 0.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.12 |
| Profit Margin | 156.4 % |
| Operating Margin | -48.8 % |
| Return on Assets (ttm) | -0.4 % |
| Return on Equity (ttm) | 1.2 % |
| Qtrly Rev. Growth | 34.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 16.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 100.13 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|